EML4 and non-small cell lung carcinoma: Anaplastic lymphoma kinase (ALK) rearrangement, mostly echinoderm microtubule-associated protein-like 4 (EML4)-ALK fusions, is the second most common targetable genetic alteration in NSCLC, with an estimated prevalence of 3% to 5% [6].